Innovativa läkemedel
för smärtstillande på huden
Nyheter
15.01.2025
Inledande linje genomförd...
08.01.2025
Ett genombrott som gör oss stolta
A Swedish innovation with global potential
Auxesis Pharma is approaching commercialization. With patented technology, a growing product portfolio and upcoming local manufacturing in Sweden, we are building a long-term path to the global market.
For investors, this is a unique opportunity to join the journey as Swedish drug development meets international demand. We combine scientifically validated effect with a scalable business model, positioning Auxesis Pharma as a future player in innovative medicines.
Two paths to pain control
Auxesis develops preparations that block the pain signal to the brain and remove pain in the skin.
The research includes products for humans and may also be useful for pets and livestock, although certain formulations may require adaptation per species.
Different types of skin pain
Auxesis develops preparations that block the pain signal locally in the skin and remove pain where it occurs.
Scientific publications on pain, ASA and COX-2
Research
COX-2 inhibitors — Nature Scientific Reports
Research on COX-2 inhibitors and their mechanisms.
Nerve cells
Nerve cells in human skin perform advanced computations
Topical NSAIDs — Mayo Clinic
Information on topical anti-inflammatory medicines.
Karolinska Institutet — Inflammation Research
Swedish research on pain and inflammatory mechanisms.
Topical pain products on the market
Veterinary medicine & animal health
Latest from Auxesis Pharma
Nyhetsbrev Februari 2026
Read more →
Starten på nästa fas
Read more →
Läkemedelsindustrin
Read more →